Why the study?
Is subclinical systemic inflammation (hsCRP) associated with an increased risk of de novo major depressive disorder in women?
Population
644 women (aged 20-84 years) with no prior history of depression at baseline, from a population-based sample.
Design
Cohort
Follow-up
a decade (5827 person-years)
Authors
Loading...
hsCRP was associated with higher de novo MDD risk in women; supports inflammation hypothesis but leaves causality and practice change open.
Is subclinical systemic inflammation (hsCRP) associated with an increased risk of de novo major depressive disorder in women?
Serum hsCRP is an independent risk marker for de novo major depressive disorder in women, supporting an aetiological role for inflammation in depression.
Pasco et al. (2010) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: